Investor Relations

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

Press Releases Press Releases

Annual/Quarterly Reports Annual/Quarterly Reports

Current Reports Current Reports

Insider Transactions Insider Transactions

Proxy Information Proxy Information

All Filings All Filings

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Sep 12, 2023

View All News

Q2 2023

Quarter Ended Jun 30, 2023

PDF HTML

Earnings Release

PDF HTML

10-Q

ZIP XLS HTML

XBRL

Latest Annual Filing

Fiscal Year Ended Dec 31, 2022

View Filing

Stock Information

Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Acurx's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin- Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

World Antimicrobial Resistance Conference Presentation

Download World Antimicrobial Resistance Conference Presentation

Investor Contact Information

Company

Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305